Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 786 Lung Neoplasms 347 Ovarian Neoplasms 323 Breast Neoplasms 279 Fallopian Tube Neoplasms 159 Triple Negative Breast Neoplasms 146 Small Cell Lung Carcinoma 146 Neoplasms 138 Squamous Cell Carcinoma of Head and Neck 123 Carcinoma, Ovarian Epithelial 114 Neoplasm Metastasis 87 Head and Neck Neoplasms 80 Endometrial Neoplasms 77 Uterine Cervical Neoplasms 72 Esophageal Neoplasms 72 Adenocarcinoma of Lung 71 Neuroblastoma 55 Central Nervous System Neoplasms 53 Carcinoma 51 Lymphoma, Large B-Cell, Diffuse 49 Recurrence 48 Brain Neoplasms 48 Prostatic Neoplasms 44 Parkinson Disease 4, Autosomal Dominant Lewy Body 44 Urinary Bladder Neoplasms 42 Esophageal Squamous Cell Carcinoma 41 Lymphoma 39 Melanoma 35 Carcinoma, Squamous Cell 33 Stomach Neoplasms 31

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Carboplatin × Clear all

NCT06743126 2026-06-10

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡